[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"photobiomodulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:photobiomodulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,80,105,136,164,189,221,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638363","photobiomodulation-effects-on-fatigue-and-muscle-damage-induced-by-nmes-100638363",false,"NCT07602933","Photobiomodulation Effects on Fatigue and Muscle Damage Induced by NMES","Effects of Photobiomodulation on Fatigue and Muscle Damage Induced by Neuromuscular Electrical Stimulation in Healthy Individuals: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Healthy male and female volunteers.\n* Age between 18 and 45 years.\n* Practice physical activity regularly\n* No history of musculoskeletal injuries in the lower limbs in the last 6 months\n* Ability to tolerate NMES\n\nExclusion Criteria:\n\n* Have sensory intolerable changes due to NMES\n* Consumed coffee or another stimulant in the last 12 hours\n* Have a body mass index (BMI) greater than 30 kg\u002Fm2 (grade I obesity)\n* Present any contraindication for the performance of maximum effort\n* Abnormal increase in blood pressure after maximal exertion",true,"ALL","18 Years","45 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","Neuromuscular electrical stimulation (NMES) is widely used to improve muscle strength and mitigate atrophy. However, its clinical efficacy is often limited by early neuromuscular fatigue, muscle damage, and discomfort, which reduce patient tolerance and contraction time. Photobiomodulation (PBM) has emerged as a potential therapy to enhance muscle performance and accelerate recovery by minimizing fatigue and damage. Despite its potential, few studies have investigated the effects of PBM applied specifically before an NMES-evoked fatigue protocol. This randomized, double-blind, placebo-controlled trial aims to evaluate the acute effects of PBM on neuromuscular fatigue, muscle damage, and functional outcomes in healthy young subjects. Participants will receive either active PBM (cluster probe: 5 lasers 810nm\u002F200mW; 4 LEDs 660nm\u002F10mW; Total Energy: 249.6 J per limb) or sham treatment 5 minutes before a fatiguing NMES protocol (80 contractions at 20% MVIC, 80 Hz, 1ms pulse width) applied to the quadriceps muscle. Assessments will be performed at baseline, immediately post-intervention, and at 24h, 48h, and 72h post-intervention. Primary outcomes include maximum and evoked isometric strength, mechanical work, and electrical muscle activity. Secondary outcomes include muscle damage (ultrasound echo-intensity), delayed onset muscle soreness (DOMS), functional performance (unilateral vertical jump), and clinical discomfort. The study seeks to determine if PBM can effectively modulate NMES-induced fatigue and muscle damage, potentially optimizing its clinical application.",[28,29,30,31,32],"Photobiomodulation","Fatigue","Discomfort","Electrical Stimulation","Muscle Damage",[28,29,30,32,34],"Electrical stimulation","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":22},"2026-06-01",{"date":43,"type":22},"2026-09-30",{"name":45,"class":46},"Federal University of Rio Grande do Sul","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100640941","evaluating-how-red-light-therapy-applied-to-the-head-affects-symptoms-daily-life-and-brain-activity-in-people-with-dementia-with-lewy-bodies-100640941","NCT07602296","Evaluating How Red-light Therapy Applied to the Head Affects Symptoms, Daily Life, and Brain Activity in People With Dementia With Lewy Bodies","Effect of Transcranial Photobiomodulation on Clinical Symptoms, Quality of Life and Cerebral Connectivity Modifications in Dementia With Lewy Bodies","LewyLIGHT","Inclusion criteria:\n\n* Man or woman, 50 years or older\n* Probable DLB diagnosed according to the criteria of McKeith et al., 2017, or the criteria of McKeith et al., 2020 for prodromal DLB\n* Score on the Mini Mental State Examination (MMSE; Folstein et al., 1983) ≥ 18\u002F30 at their last medical visit\n* Good mastery of the French language\n* Accompanied by a caregiver or a person able to provide information about them (interview, by telephone).\n* Able to understand the objectives and risks associated with the research and to give informed consent, dated and signed\n* Covered by a social health insurance plan\n* Having a head circumference between 54 and 62 cm.\n\nExclusion criteria:\n\n* Not able to understand the objectives and risks related to research and to give informed consent\n* Presence of another neurological disorder, including but not limited to brain tumors, stroke with potential cognitive impairment, or diagnosis of another progressive neurological disease (e.g., Alzheimer's disease, Parkinson's disease, etc.), and as determined by the investigator\n* Having an MMSE score \\\u003C 18 at the screening visit\n* Unable to undergo a brain MRI due to medical reasons\n* Participants whose follow-up would likely be disrupted during the study period (e.g., due to planned relocation or other reasons)\n* Insufficient proficiency of the French language\n* Participants experiencing an emergency of life-threatening situation\n* Alone, without a caregiver present\n* Participants presenting with a head\u002Fscalp injury\n* Participants with a silicone allergy\n* Participants with cranial\u002Fskull shape abnormalities\n* Participants with a head circumference outside the range of 54-62 cm\n* Participants requiring life support, continuous monitoring, and\u002For implanted medical devices (AIMD)\n* Participants taking the antiepileptic Keppra (Levetiracetam)\n* Participants whose anticholinesterase treatments have been changed within the past 2 months\n* Participants whose antipsychotic treatments have been changed within the last 15 days\n* Pregnant or breastfeeding women","50 Years",{"count":58,"type":22},40,[25],"Dementia with Lewy bodies (DLB) is a neurodegenerative disease diagnosed primarily based on the presence of cognitive decline, which may include difficulties with memory, attention, and more. Additionally, at least two of the following symptoms are needed for a probable diagnosis of DLB, and at least one for a possible DLB diagnosis (McKeith et al. 2017 and 2020):\n\n* Fluctuations in cognition, attention, and\u002For alertness\n* Visual hallucinations\n* Spontaneous parkinsonism\n* REM sleep behavior disorder\n\nPatients with DLB can experience cognitive deficits that can fluctuate and can vary for each patient. These may include deficits in memory, executive functions (planning and organizing), attention, visual processing, and language.\n\nThis study aims to evaluate the effect of red-light therapy, delivered using a helmet that contains small LED lights, in patients with DLB.\n\nParticipants' cognitive functions, clinical symptoms, quality of life and functional cerebral connectivity will be evaluated before starting therapy and again after three and six months of twice daily therapy use. As DLB also indirectly affects caregivers, the caregiver's quality of life and burden will also be evaluated before and at three and six months of therapy use by the participant.\n\nThe study's inclusion period is 24 months and the duration of participation for each patient is 8 months (+\u002F-10 days) maximum.",[28,62],"Dementia With Lewy Bodies",[64,65,66,67,68,69],"Photobiomodulation (PBM)","Dementia with Lewy bodies (DLB)","Cognitive functions","Clinical symptoms","Quality of life","Cerebral connectivity","NOT_YET_RECRUITING","2026-06-18",{"date":73,"type":39},"2026-06-23",{"date":75,"type":22},"2026-06",{"date":77,"type":22},"2029-03",{"name":79,"class":46},"University Hospital, Strasbourg, France",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100628381","effectiveness-of-photobiomodulation-for-myofascial-pain-in-temporomandibular-disorders-100628381","NCT07460895","Effectiveness of Photobiomodulation for Myofascial Pain in Temporomandibular Disorders","Photobiomodulation in the Management of Myofascial Pain: A Randomized and Blinded Clinical Trial","Inclusion Criteria:\n\n* Individuals with myofascial TMD (ICD-9 729.1; ICD-10 M79.1) diagnosed according to the DC\u002FTMD criteria;\n* Participants aged 18 years or older;\n* Individuals able to communicate, read, write, and provide written informed consent in Portuguese.\n\nExclusion Criteria:\n\n* Patients with a history of autoimmune connective tissue diseases, such as rheumatoid arthritis, psoriatic arthritis, scleroderma, or systemic lupus erythematosus;\n* History of malignancy in the head and neck region within the past 2 years (except basal cell carcinoma) who have undergone head and neck radiation therapy and\u002For surgery affecting facial muscles;\n* Patients who have undergone temporomandibular joint surgery or orthognathic surgery;\n* Pregnant or breastfeeding women;\n* Patients with poorly adapted prostheses and\u002For prostheses associated with inadequate increase or decrease of the vertical dimension;\n* Patients with a history of tardive dyskinesia or oromandibular\u002Fcervical dystonia; -Patients with maximum mouth opening less than 35 mm;\n* Patients using systemic medications with a potential effect on pain at the time of screening will not be included in the study, including analgesics, anti-inflammatory drugs, muscle relaxants, corticosteroids, or other medications with analgesic and\u002For anti-inflammatory effects.\n\nIf a participant initiates the use of any such medication during the follow-up period, the participant will be excluded from the study.\n\n\\- Patients receiving oral and\u002For intravenous corticosteroid bolus therapy at doses \\> 1 mg\u002Fkg within the past 3 months, and those receiving biologic agents within 1 month or five times the drug half-life, whichever is longer; Individuals with mental or psychological conditions that may prevent participation in the study.",{"count":88,"type":22},140,[25],"This randomized clinical trial aims to evaluate the effectiveness of photobiomodulation therapy (PBM) alone or combined with therapeutic exercises compared with placebo PBM associated with exercises in patients with myofascial temporomandibular disorders (TMD). Participants will be allocated into three groups: PBM alone, PBM combined with exercises, or placebo PBM combined with exercises. The intervention consists of 12 treatment sessions. Outcomes related to pain intensity, mandibular function, and clinical measures will be assessed over time. The study seeks to investigate whether PBM provides additional benefits in pain reduction and functional improvement in individuals with myofascial TMD.",[28,92,93,94],"Temporomandibular Disorder (TMD)","Myofacial Pain","Pain Management",[28,96,97,94],"Myofascial Pain","Temporomandibular Disorder","2026-03-05",{"date":100,"type":39},"2026-03-10",{"date":100,"type":22},{"date":103,"type":22},"2030-12",{"name":45,"class":46},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":47},"100600289","impact-of-ndyag-laser-photobiostimulation-on-healing-of-gingiva-100600289","NCT07095556","Impact of Nd:YAG Laser Photobiostimulation on Healing of Gingiva","Impact of Nd: YAG Laser Photobiostimulation on Healing of Gingiva Following Tooth Extraction and Alveolar Ridge Preservation","Inclusion Criteria:\n\n* Participants who are ≥ 18 years old,\n* Patients who are scheduled for the treatment of tooth extraction and alveolar ridge preservation (ARP)\n* No contraindications for tooth extraction and alveolar ridge preservation based on electronic health records.\n* Participants who can express the level of pain\n* Participants who self-report \"not pregnant\"\n\nExclusion Criteria:\n\n* Untreated periodontal disease\n* Acute infection of the teeth\n* Use of antibiotics within the last three months.\n* Pregnant or lactating women\n* Use of bisphosphonates based on EHR\n* Alveolar bone defects occurred or were detected during tooth extraction",{"count":113,"type":22},39,[25],"The intervention in this study is to determine whether multiple applications of photobiostimulation with Nd-YAG laser improve wound healing following tooth extraction and alveolar ridge preservation. Investigators plan to assess the impact of laser treatment on wound healing by measuring salivary biomarkers, gingival wound size and surveying for the use of pain reduction and patient satisfaction. The intervention group will receive extraction and alveolar ridge preservation with Nd-YAG laser photobiostimulation on days 1, 3, and 7 following extraction and socket preservation, while the control group will receive the standard of care extraction and alveolar ridge preservation without the laser",[117,118,28,119,120],"Wound Healing and Prevention","Oral Inflammation","Post-operative Pain Management","Tooth Extraction Site Healing",[122,123,124,125,126],"Inflammation","Periodontal Disease","low-level laser therapy","gingival healing","Post-operative pain","2025-11-07",{"date":129,"type":39},"2025-11-12",{"date":131,"type":39},"2025-11-05",{"date":133,"type":22},"2027-04-30",{"name":135,"class":46},"Medical University of South Carolina",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100596316","effects-and-feasibility-of-photobiomodulation-at-830nm-nanometers-in-the-treatment-of-diabetic-ulcers-100596316","NCT07043868","Effects and Feasibility of Photobiomodulation at 830nm Nanometers in the Treatment of Diabetic Ulcers","Effects and Feasibility of Photobiomodulation at 830 Nanometers in the Treatment of Diabetic Ulcers: a Randomized, Double-blind Clinical Trial","Inclusion Criteria:\n\n* Volunteers of both sexes\n* Age over 18 years\n* Medical diagnosis of diabetes mellitus (DM)\n* Presence of diabetic ulcer\n\nExclusion Criteria:\n\n* Autoimmune diseases\n* Infected diabetic ulcers\n* Osteomyelitis\n* Ischemia\n* Concomitant psychiatric disorders\n* Contraindications to treatment methods",{"count":144,"type":22},136,[25],"Diabetic foot ulcers (DFU) are among the late complications of DFU, defined as skin lesions that involve the dermis to deeper structures, such as muscles and bones. Although preclinical studies have demonstrated the effects of GaAs 830 nm in diabetic wounds, no clinical studies have been performed, revealing the need for more in-depth analyses to identify the effects and ideal parameterization of PBM with GaAs 830 nm wavelength in the treatment of diabetic ulcers, improving quality of life, as well as to understand the therapeutic feasibility, time required for healing and recurrence rates of these lesions. Experimental, randomized, controlled, double-blind study, with blinding applied to the evaluator and participants. A total of 136 volunteers will be recruited for the research, carried out at the Integrated Center of Medical Specialties (CIEM) - Polyclinic. LLLT GaAs 830nm will be used with three dosages of low, medium and high intensity (4 J\u002Fcm², 8 J\u002Fcm², 12 J\u002Fcm²). The study will have three intervention groups using LLLT with GaAs 830nm and a control group, in which LLLLT will be performed with a GaAs 904nm wavelength and a dose of 10 J\u002Fcm², according to Saura et al (2024). This study was approved by the local Research Ethics Committee (Opinion 7,488,044), conducted in accordance with the Declaration of Helsinki and in accordance with the CONSORT (Consolidated Standards of Reporting Trials) guidelines.",[148,149,28,150],"Diabete Type 2","Diabetic Foot Ulcer","Low Level Laser Therapy",[152,153,154],"diabetic foot ulcer","photobiomodulation","low level laser therapy","2025-07-05",{"date":157,"type":39},"2025-07-10",{"date":159,"type":22},"2026-01-10",{"date":161,"type":22},"2028-01-10",{"name":163,"class":46},"Federal University of Piaui",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":47},"100511120","effect-of-photobiomodulation-to-reduce-post-operative-pain-after-endodontic-surgery-100511120","NCT05935306","Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery","Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery: a Randomized Controlled Clinical Trial","Inclusion Criteria\n\n:• Patients with periapical lesions who have already undergone endodontic treatment (lesions smaller than 10mm in their greatest diameter - Metin et al., 2018, single and chronic lesions)\n\n* Patients with not comorbidities,\n* Age from 18 to 70 years,\n* Both genders,\n* Healthy permanent teeth with good hygiene.\n\nExclusion Criteria:\n\n* Who are taking drugs that affect bone metabolism and the inflammatory process (for example: corticosteroids, bisphosphonates),\n* Smokers, pregnant or lactating women,\n* Who used anti-inflammatory drugs in the last 3 months before surgery.\n* Who for any reason interrupted the evolution of the treatment for not attending joint appointments.\n* Patients who do not follow the guidelines or have an injury in the acute phase (pain, edema, exudate)","70 Years",{"count":173,"type":22},34,[25],"The objective of this study will be to evaluate if photobiomodulation (FBM) can reduce postoperative pain in patients who will undergo endodontic surgery. For this randomized, controlled and double-blind clinical study, 34 patients without comorbidities who need endodontic surgery in the upper jaw (15 to 25 teeth) will be recruited. They will be randomly divided into an experimental group (n = 17) photobiomodulation (808nm, 100 mW, and 4J\u002Fcm2 with 5 points per vestibular). Applications will be made in the immediate postoperative period and 24 hours after surgery. Control group (n = 17) a FBM simulation will be performed in the same way as in the experimental group. In this group, the required analgesia will be administered within the standard with ibuprofen. Both groups will perform the necessary conventional procedures considered the gold standard in the literature. Both the patient and the evaluator will be blinded to the intervention performed. The primary outcome variable of the study will be postoperative pain, which will be assessed using the visual analog scale at all postoperative control visits (baseline, 24 hours and 7 days). As for the secondary outcome variables, the amount of systemic medication received according to the patient's need (will be provided by the investigator).. Radiographic images will be obtained after 1 and 2 months for evaluation of the repair (dimensions of the lesion, radiopacity). These radiographs will be taken digitally with the positioners implemented. Edema, ecchymosis, and evaluation of soft tissues in the anterior portion of the intra and extra-oral maxilla will also be evaluated. In addition, a digital thermometer. These parameters will be evaluated 24 hours and 7 days after the intervention. The X-rays will be taken in the 1st and 3rd month respectively.",[28,177,178,122,179],"Endodontic Disease","Pain","Surgery","2025-05-03",{"date":182,"type":39},"2025-05-07",{"date":184,"type":39},"2024-06-30",{"date":186,"type":22},"2025-12-01",{"name":188,"class":46},"University of Nove de Julho",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":47},"100565304","early-phase-1-led-therapy-for-third-molar-surgery-100565304","NCT06640439","LED Therapy for Third Molar Surgery","LED Therapy Using 830 Nm in the Mandibular Third Molar Surgery: Double-blind Randomized Clinical Trial.","LTTMS","Inclusion Criteria:\n\n1. Healthy Asians;\n2. 20-55 years old;\n3. Having mandibular third molars that are inappropriately erupted and need to be extracted due to caries, orthodontic reasons and\u002For periodontal disease;\n\nExclusion Criteria:\n\n1. Underlying diseases: diabetes, cardiovascular disease, coagulation disorder, osteoporosis, hypertension, neurological disease, psychological disorder, tumor, systemic infection or cyst at the extraction site;\n2. Women who are preparing for pregnancy, pregnant or breastfeeding;\n3. Medication history: use of analgesics, anti-inflammatory drugs and\u002For antibacterial drugs 2 weeks before tooth extraction, need for systemic medication other than acetaminophen after surgery, allergy to acetaminophen, use of anticoagulants, bisphosphonates;\n4. Bad habits, such as addicted to smoking, drinking, etc.;\n5. Volunteers who have recently participated in other clinical trials;","20 Years","55 Years",{"count":200,"type":22},50,[202],"EARLY_PHASE1","LED Therapy for third molar surgery",[205,28,206,207],"Molar, Third","Photobiomodulation Therapy","Third Molar Surgery",[153,209,210,211],"LED","830 nm","third molar surgery","2024-10-10",{"date":214,"type":39},"2024-10-15",{"date":216,"type":22},"2024-10-14",{"date":218,"type":22},"2025-04-14",{"name":220,"class":46},"Huashan Hospital",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":47},"100510265","preventive-effect-of-photobiomodulation-in-the-postoperative-period-of-extractions-of-retained-lower-third-molars-100510265","NCT05924191","Preventive Effect of Photobiomodulation in the Postoperative Period of Extractions of Retained Lower Third Molars","Evaluation of the Preventive Effect of Photobiomodulation in the Postoperative Period of Extractions of Retained Lower Third Molars: a Double-blind Randomized Controlled Study","Inclusion Criteria:\n\n* Patients who present retained lower third molars, according to the degree of surgical difficulty of the procedure and the anatomical position.The selected molars will be those classified according to classes II and III and\u002For B or C of Pell and Gregory Classification; in vertical or mesio-angular position, according to the Winter Classification or Class II with need for ostectomy or III, with need for ostectomy and odontosection of the Prant Scale, modified by Amarillas-Escobar et al.\n* That have an indication for the extraction of the lower third molars (due to recurrent infections, bad anatomical position, orthodontic indication) or a professional indication presented in writing and that are healthy (ASA I, with a negative medical history).\n* Male or female gender.\n* Age between 18 and 50 years.\n* Good oral hygiene.\n* That they agree to participate in the study, after reading and signing the Informed Consent for participation in clinical research.\n\nExclusion Criteria:\n\n* Carriers of local alterations that contraindicate surgical intervention or complicate the postoperative period (example: acute phase pericoronitis in the last 30 days, ankylosis of the temporomandibular joint).\n* Smokers,\n* Presenting absence of upper and lower central incisors,\n* With a medical history of photosensitivity\n* During pregnancy or lactation,\n* That they were using anti-inflammatories or analgesics,\n* Allergic to any of the drugs used in the research (amoxicillin, ketorolac, acetaminophen, dexamethasone, chlorhexidine 2%, local anesthetics, sodium bisulfite, etc.)\n* That during surgery they present any type of complication (bleeding, transoperative difficulties, etc.), because these cases are not included within the expected pattern behavior for this type of surgery (these cases will be reported),\n* Surgical time greater than 90 minutes.",{"count":229,"type":22},30,[25],"Third molar extraction is one of the most performed surgical procedures in Dentistry. A comfortable postoperative period and rapid return to daily activities increase the need to control the inflammatory response and its signs and symptoms such as pain, edema, and lockjaw. Therefore, the objective of this study is to evaluate the efficacy of the prophylactic use of Photobiomodulation in the reduction of edema in the postoperative period of extractions of retained lower third molars.The primary study variable will be postoperative edema measured in millimeters, 48 hours after surgery, and the secondary variables will be: pain, lockjaw, local temperature (measured with a thermographic camera), dysphagia, and the need to ingest nonsteroidal analgesics (Acetaminophen)These variables will be evaluated at the beginning of the study (baseline), at 2 and 7 days post-surgery. All adverse effects will be recorded. The data obtained will be represented by their means ± SD and the p value will be set at 0.05.",[205,28],[153,234,235,236,237,238,239,240],"corticosteroids","extraction","edema","pain","mouth opening","quality of life","randomized clinical trial","2024-07-04",{"date":243,"type":39},"2024-07-08",{"date":245,"type":39},"2023-11-20",{"date":247,"type":22},"2024-07-20",{"name":188,"class":46},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":4},"100478274","photobiomodulation-for-dry-age-related-macula-degeneration-100478274","NCT05507840","Photobiomodulation for Dry Age Related Macula Degeneration","Inclusion Criteria:\n\n* patients with dry AMD in the study eye and wet AMD in the control eye\n\nExclusion Criteria:\n\n* Geographic atrophy of the central macular region at enrolment\n* Previous\u002F active wet AMD in the study eye\n* A history of epilepsy\n* Retinal diseases apart from AMD\n* Significant media opacities\n* Cataracts worse than grade 2 (LOCS III classification)\n* Change in AREDS 2 supplements (vitamins) 1 month before the study and during the study trial was allowed.\n* Ongoing systemic medications that are photosensitizing (e.g. tetracyclins)\n* Systemic medications during the last 6 months that can cause deposits in the macular region (hydroxychloroquine, amiodarone)\n* Unable to give informed consent\n* Unable to cooperate with the treatment and follow-up",{"count":256,"type":22},121,[25],"The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.",[28,260],"Age-Related Macular Degeneration",[262],"choroidal neovascular membrane","2022-10-11",{"date":265,"type":39},"2022-10-12",{"date":267,"type":22},"2022-12-01",{"date":269,"type":22},"2027-12-01",{"name":271,"class":46},"Oslo University Hospital"]